Novavax Completes Construction of Vaccine Production Facility in India

June 11, 2010

CPL Biologicals, a joint venture of Cadila Pharmaceuticals Ltd. (Ahmendabad, India) and Novavax, Inc. (Rockville, MD), has completed construction of its vaccine facility in Dholka, India.

CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals Ltd. (Ahmendabad, India) and Novavax, Inc. (Rockville, MD), has completed construction of its vaccine facility in Dholka, India. CPLB will commence equipment and installation validation this month so the facility will conform to global standards for production of vaccines for human use.

The new facility uses state-of-the-art equipment for the potential production of up to 60 million doses of vaccines every year. The facility plans to produce seasonal and pandemic flu vaccines based on Novavax's virus-like particle (VLP) technology that enables the rapid development and production of vaccines without the use of live virus.

In addition to vaccine production, CPLB also is focused on the development, manufacture, and sale of biosimilars and diagnostic kits.